SCHEMBL84050

SCHEMBL84050

C=P(C)(C)CC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL889879 0.76
SCHEMBL15294568 0.73
SCHEMBL23555364 0.73
SCHEMBL141187 0.73
SCHEMBL22525063 0.73
SCHEMBL15116997 0.70
SCHEMBL14963602 0.70
SCHEMBL22477584 0.70
SCHEMBL4763104 0.70
SCHEMBL13104902 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-07-18 US disclosed
US-11826485-B2 Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) 2023-11-28 US disclosed
US-11708347-B2 Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2023-07-25 US disclosed
US-20200231620-A1 TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION WAVE LIFE SCIENCES LTD. (SG) 2020-07-23 US disclosed
US-10023861-B2 Oligomer-conjugate complexes and their use IONIS PHARMACEUTICALS, INC. (US) 2018-07-17 US disclosed
US-9976138-B2 Methods and compounds useful in conditions related to repeat expansion IONIS PHARMACEUTICALS, INC. (US) 2018-05-22 US disclosed
US-20170267681-A1 ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES MIDCAP FINANCIAL TRUST, AS AGENT 2017-09-21 US disclosed
US-20170216272-A1 COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2017-08-03 US disclosed
WO-2017093543-A2 ANTI-BACTERIAL COMPOUNDS AUSPHERIX LIMITED (GB) 2017-06-08 WO disclosed
US-9629840-B2 Aminopyrimidine kinase inhibitors Jasco Pharmaceuticals, LLC (US) 2017-04-25 US disclosed
US-7186822-B2 Process for the synthesis of oligomeric compounds ISIS PHARMACEUTICALS, INC. (US) 2007-03-06 US disclosed
US-20070032620-A1 Chemical vapor deposition of hydrogel films MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2007-02-08 US disclosed
US-20070020309-A1 Safe and effective biofilm inhibitory compounds and health related uses thereof CUTLER, ELIOT 2007-01-25 US disclosed
US-20070021493-A1 Mediators of hedgehog signaling pathways, compositions and uses related thereto CURIS, INC. (US) 2007-01-25 US disclosed
US-20070020384-A1 Environmentally benign crop protection agents CUTLER, ELIOT 2007-01-25 US disclosed
US-20070015768-A1 Ubiquitin ligase inhibitors and methods related thereto PROTEOLOGICS, LTD. (IL) 2007-01-18 US disclosed
US-7160732-B2 Fluorescein-based metal sensors, and methods of making and using the same MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2007-01-09 US disclosed
US-7157429-B1 Inhibiting the dipeptidylpeptidase proteolysis of Glucagon-like peptide, by administering a dipeptides consisting Pro-Pro, Ala-Pro, and (D)-Ala-(L)-Ala; treating metabolism disorders, diabetes, obesity, atherosclerosis TRUSTEES OF TUFTS COLLEGE (US) 2007-01-02 US disclosed
US-20050070578-A1 Small organic molecule regulators of cell proliferation CURIS, INC. 2005-03-31 US disclosed
US-20040176307-A1 Inhibiting dipeptidylpeptidase proteolysis of glucagon-like peptide 1 ARISAPH PHARMACEUTICALS, INC. 2004-09-09 US disclosed